Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2023-03-29 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
2022年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2022 of 东北制药集团股份有限公司. It contains detailed audit opinions, basis for audit opinions, key audit matters, management responsibilities, and extensive financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report rather than a full annual report (10-K) or other filings. Therefore, the document fits the category of Audit Report / Information (AR).
2023-03-29 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled "内部控制审计报告" which translates to "Internal Control Audit Report" for the year ended December 31, 2022. It is addressed to the shareholders and prepared by an accounting firm (Grant Thornton). The content discusses the audit of the effectiveness of internal control over financial reporting, responsibilities of the company and auditors, inherent limitations of internal control, and the audit opinion on internal control effectiveness. This is a standalone audit report focused on internal control over financial reporting, not a full annual report or financial statement. It matches the description of an Audit Report / Information (AR) filing, which includes audit reports and applied accounting principles but excludes full annual reports. The document length (8887 characters) and detailed audit content support this classification rather than a brief announcement or certification. Therefore, the filing type is AR with high confidence.
2023-03-29 Chinese
关于公司2022年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its 2022 annual asset impairment provisions, including detailed explanations of the impairment testing, amounts, and impacts on profits. It includes references to board and supervisory meetings approving the impairment provisions and mentions an audit report with an unqualified opinion. The document is relatively short (3605 characters) and primarily serves as a formal announcement of the impairment provision decision and its financial impact, rather than a full annual report or audit report. It does not contain comprehensive financial statements or full audit details but summarizes the impairment provision and related approvals. Therefore, it fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about asset impairment provisions and related board approvals, not a full Annual Report (10-K) or standalone Audit Report (AR).
2023-03-29 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2022 年年度报告全文" which translates to "2022 Annual Report Full Text" for Northeast Pharmaceutical Group Co., Ltd. It contains detailed sections including company overview, financial data, management discussion and analysis, governance, social responsibility, and full financial statements. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial data, management analysis, and detailed business descriptions, consistent with a full annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-03-29 Chinese
2022年度监事会工作报告
Board/Management Information Classification · 90% confidence The document is titled as the "2022年度监事会工作报告" (2022 Supervisory Board Work Report) of Northeast Pharmaceutical Group Co., Ltd. It details the supervisory board's activities, meetings, oversight of financial reports, internal controls, and compliance with laws and regulations during the 2022 fiscal year. The content includes descriptions of supervisory board meetings, audit opinions, internal control evaluations, and plans for 2023. The document is a detailed report on the supervisory board's work rather than an announcement or a brief summary. It does not fit the definitions of Annual Report (10-K), Audit Report (AR), or Interim Report (IR) exactly, but it is a formal report related to governance and oversight activities. Given the nature of the content focusing on supervisory board work and governance oversight, the best fitting category is Board/Management Information (MANG). The document length is 3459 characters, which is relatively short but contains substantive content rather than just an announcement or certification. Therefore, the classification is MANG with high confidence.
2023-03-29 Chinese
关于公司2022年度日常关联交易执行情况及2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the company's related party transactions for the fiscal year 2022 and the expected related party transactions for 2023. It includes transaction amounts, pricing principles, independent directors' opinions, and board meeting resolutions. The content focuses on disclosure of related party transactions, which is a regulatory requirement for listed companies to ensure transparency and fairness. It is not a full annual report, audit report, or financial statement. It is also not a voting result, management change, or earnings release. The document is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories and is a compliance disclosure.
2023-03-29 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.